Recent Advances in Mode of Action and Biosynthesis Studies of the Clinically Used Antibiotic Fidaxomicin

被引：11
作者：
Dorst, Andrea [1 ]
Jung, Erik [1 ]
Gademann, Karl [1 ]
机构：
[1] Univ Zurich, Dept Chem, Winterthurerstr 190, CH-8057 Zurich, Switzerland
来源：
CHIMIA | 2020年 / 74卷 / 04期
关键词：
Antibiotics; Biosynthesis; Mode of action; Natural products; SAR studies; ARMENIACA SUBSP NOV; TIACUMICIN-B; RNA-POLYMERASE; NATURAL-PRODUCT; LIPIARMYCIN A3; CO-IDENTITY; IN-VITRO; INITIATION; CLOSTOMICINS; ACTINOPLANES;
D O I：
10.2533/chimia.2020.270
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
The natural product antibiotic fidaxomicin is a marketed drug for the treatment of bacterial infections in the gut. Due to its promising in vitro activities against Mycobacterium tuberculosis, the development of next generation fidaxomicin analogs is of great interest. This article reviews the most recent advances, including the elucidation of a unique mode of action by cryo-EM structures, and the efforts towards the clarification of the biosynthetic pathway. Moreover, known fidaxomicin analogs and their reported antibacterial activities are summarized.
引用
收藏
页码：270 / 273
页数：4
相关论文
共 53 条
[1]   STRUCTURE ELUCIDATION OF THE MACROCYCLIC ANTIBIOTIC LIPIARMYCIN [J].
ARNONE, A ;
NASINI, G ;
CAVALLERI, B .
JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 1, 1987, (06) :1353-1359
[2]   Fidaxomicin Is an Inhibitor of the Initiation of Bacterial RNA Synthesis [J].
Artsimovitch, Irina ;
Seddon, Jaime ;
Sears, Pamela .
CLINICAL INFECTIOUS DISEASES, 2012, 55 :S127-S131
[3]   Comparative Microbiological Studies of Transcription Inhibitors Fidaxomicin and the Rifamycins in Clostridium difficile [J].
Babakhani, Farah ;
Seddon, Jaime ;
Sears, Pamela .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (05) :2934-2937
[4]   Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile [J].
Babakhani, Farah ;
Gomez, Abraham ;
Robert, Nikki ;
Sears, Pamela .
JOURNAL OF MEDICAL MICROBIOLOGY, 2011, 60 (08) :1213-1217
[5]  
Bedeschi A, 2016, NAT PROD COMMUN, V11, P569
[6]   In Vitro Activity of Fidaxomicin (OPT-80) Tested against Contemporary Clinical Isolates of Staphylococcus spp. and Enterococcus spp. [J].
Biedenbach, Douglas J. ;
Ross, James E. ;
Putnam, Shannon D. ;
Jones, Ronald N. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (05) :2273-2275
[7]   Fidaxomicin jams Mycobacterium tuberculosis RNA polymerase motions needed for initiation via RbpA contacts [J].
Boyaci, Hande ;
Chen, James ;
Lilic, Mirjana ;
Palka, Margaret ;
Mooney, Rachel Anne ;
Landick, Robert ;
Darst, Seth A. ;
Campbell, Elizabeth A. .
ELIFE, 2018, 7
[8]   LIPIARMYCIN, A NEW ANTIBIOTIC FROM ACTINOPLANES .2. ISOLATION, CHEMICAL, BIOLOGICAL AND BIOCHEMICAL CHARACTERIZATION [J].
CORONELLI, C ;
WHITE, RJ ;
LANCINI, GC ;
PARENTI, F .
JOURNAL OF ANTIBIOTICS, 1975, 28 (04) :253-259
[9]  
Coronelli C., 1976, US Patent, Patent No. 3978211
[10]   World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions [J].
Di Angelantonio, Emanuele ;
Kaptoge, Stephen ;
Pennells, Lisa ;
De Bacquer, Dirk ;
Cooney, Marie Therese ;
Kavousi, Maryam ;
Stevens, Gretchen ;
Riley, Leanne ;
Savin, Stefan ;
Altay, Servet ;
Amouyel, Philippe ;
Assmann, Gerd ;
Bell, Steven ;
Ben-Shlomo, Yoav ;
Berkman, Lisa ;
Beulens, Joline W. ;
Bjorkelund, Cecilia ;
Blaha, Michael J. ;
Blazer, Dan G. ;
Bolton, Thomas ;
Bonita, Ruth ;
Brenner, Beaglehole Hermann ;
Brunner, Eric J. ;
Casiglia, Edoardo ;
Chamnan, Parinya ;
Choi, Yeun-Hyang ;
Chowdhury, Rajiv ;
Coady, Sean ;
Crespo, Carlos J. ;
Cushman, Mary ;
Dagenais, Gilles R. ;
D'Agostino, Ralph B. ;
Daimon, Makoto ;
Davidson, Karina W. ;
Engstrom, Gunnar ;
Fang, Xianghua ;
Ford, Ian ;
Gallacher, John ;
Gansevoort, Ron T. ;
Gaziano, Thomas Andrew ;
Giampaoli, Simona ;
Grandits, Greg ;
Grimsgaard, Sameline ;
Grobbee, Diederick E. ;
Gudnason, Vilmundur ;
Guo, Qi ;
Humphries, Steve ;
Iso, Hiroyasu ;
Jukema, J. Wouter ;
Kauhanen, Jussi .
LANCET GLOBAL HEALTH, 2019, 7 (10) :E1332-E1345
123456